Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel

Jochem W. van Werkum; Yasemin Topcu; Sonja Postma; Johannes C. Kelder; Christian M. Hackeng; Jurrien M. ten Berg; Freek W. A. Verheugt

doi:10.1160/TH07-07-0465

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(03): 637-639
DOI: 10.1160/TH07-07-0465

Letters to the Editor

Schattauer GmbH

Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel

Authors

Jochem W. van Werkum^*

¹Department of Cardiology
Yasemin Topcu^*

¹Department of Cardiology
Sonja Postma

²Department of Clinical Chemistry, St. Antonius Hospital, Nieuwegein, the Netherlands
Johannes C. Kelder

¹Department of Cardiology
Christian M. Hackeng

²Department of Clinical Chemistry, St. Antonius Hospital, Nieuwegein, the Netherlands
Jurrien M. ten Berg

¹Department of Cardiology
Freek W. A. Verheugt

³Department of Cardiology, UMC Nijmegen, The Netherlands

Abstract

Full Text

References

References
1 Steinhubl SR, Berger PB, Mann JT. III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
2 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
3 Van Werkum JW, Heestermans AACM, Deneer VHM. et al. Clopidogrel resistance: fact or fiction?. Future Cardiol 2006; 2: 215-228.
4 Sibbing D, von Beckerath O, Schomig A. et al. Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. J Thromb Haemost 2006; 4: 2566-2568.
5 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
6 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
7 von Beckerath N, Pogatsa-Murray G, Wieczorek A. et al. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95: 910-911.
8 Van Werkum JW, van der Stelt CA, Seesing TH. et al. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 4: 2516-2518.
9 Geisler T, Anders N, Paterok M. et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30: 372-374.
10 Michelson AD, Linden MD, Furman MI. et al. Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. J Thromb Haemost 2007; 5: 75-81.
11 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
12 Frere C, Cuisset T, Quilici J. et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.